Clinical Trial Update: Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating MP-424 with peginterferon alfa-2b and ribavirin in treatment-naïve chronic hepatitis C has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• MP-424
• Peginterferon alfa-2b (Peginterferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2012-08-20